Asian Spectator

.
Business Advice

.

Octa’s compelling Ramadan 2023—Memories which become templates for the future

KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 27 March 2024 - It is time to recall all the Ramadan initiatives the international broker Octa has launched and curated throughout the last year. C...

Moonbug Entertainment Announces Major Expansion Across China W...

LONDON, March 31, 2021 /PRNewswire-AsiaNet/ -- -- Makes Global Sensation 'CoComelon' Available to Hundreds of Millions of ViewersMoonbug Entertainment Ltd. ( https://www.moonbug.com ), one o...

IUIGA, Direct-To-Consumer Brand, Launches Solitaire Diamond Ring at Transparent Pricing with Complimentary Home Try-On

SINGAPORE - Media OutReach - 30 April 2019 - Homegrown direct-to-consumer retailer, IUIGA, is all about conscious consumerism and slow living -- and has been for the past two ...

2,700 Marriott hotel workers in Hawaii on strike, impacting gu...

WAIKIKI, Hawaii, Oct. 18, 2018 /PRNewswire-AsiaNet/ -- -- Management at the five hotels, operated by Marriott and owned by Kyo-ya, are not informing guests about the strike in advance Since ...

Nexteer Automotive Schedules 2018 Annual Results Investor Conf...

AUBURN HILLS, Michigan, March 7, 2019 /PRNewswire-AsiaNet/ -- Nexteer Automotive, a global leader in intuitive motion control, today announced that Mike Richardson, Executive Board Director ...

Tourism promotion film of China's Shanxi Province debuts on Ti...

NEW YORK, Sept. 17, 2018 /Xinhua-AsiaNet/-- A video showing the tourist attractions of China's Shanxi Province appeared on one of the digital screens of Times Square in New York from Septemb...

Kahoot! will acquire Clever, a leading US K-12 EdTech learning...

OSLO, Norway, May 6, 2021 /PRNewswire-AsiaNet/ -- Kahoot!, a global learning platform company, announced today the acquisition of Clever Inc., a privately-held, California-based company that...

World Big Data Analytics Show virtually convened India's top data and analytics leaders

INDIA, Apr 29, 2021 - (ACN Newswire) - The inaugural edition of World Big Data & Analytics Show - India, which took place on 20 April 2021, has attracted some of the prominent voices in...

Fujitsu Formulates 'Fujitsu Future Insights - Digital Transformation in Retail'

TOKYO, Nov 27, 2019 - (JCN Newswire) - Fujitsu Limited today announced its vision for the future, outlining megatrends and business opportunities of retail through the analysis of the impac...

Remap-Cap to Partner With Eisai on Innovative Trial to Combat COVID

Remap-Cap to Partner With Eisai on Innovative Trial to Combat COVID

TOKYO, Jul 1, 2020 - (JCN Newswire) - The Global Coalition for Adaptive Research (GCAR), in collaboration with UPMC (University of Pittsburgh Medical Center), and Eisai announced today that Eisai will join REMAP-COVID, a substudy of REMAP-CAP (A Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia) that tests multiple interventions for the treatment of patients hospitalized with COVID-19.Eritoran, an investigational TLR4 antagonist discovered and developed by Eisai, has been selected as the first investigational immune modulation therapy to be evaluated in the moderate patient group of REMAP-COVID. The trial will be conducted in the multi-hospital UPMC health system along with other medical centers in the United States. Additional global sites across the trial network, including Japan, will follow. Previously observed to be safe in a large Phase 3 randomized trial in sepsis, eritoran is designed to suppress the over-production and release of various pro-inflammatory mediators (cytokine storm) with the aim to protect against damage in COVID-19 patients' lungs and other organs."We are excited to initiate our partnership with Eisai and to test this promising intervention in the trial," stated Christopher Seymour, M.D, MSC, Associate Professor, Department of Critical Care Medicine(New Window) at the University of Pittsburgh and UPMC, and U.S. principal investigator of the REMAP-CAP:COVID study. "By utilizing an adaptive design rather than using a traditional trial approach, we are more likely to get to answers faster, while keeping our patients as safe as possible. REMAP-COVID is an optimal study to identify potential treatments for COVID-19 as safely, quickly, and effectively as possible.""Eisai is proud to be part of this collaborative initiative to fight the unprecedented COVID-19 pandemic. We are pleased that our investigational immune modulation therapeutic TLR4 antagonist, eritoran, will be studied alone and in combination with other drugs to evaluate the effectiveness in COVID-19 hospitalized patients," said Lynn Kramer, M.D, Chief Clinical Officer, Neurology Business Group, Eisai. "As part of our human health care mission, we are committed to making a difference for patients, their families, and health care professionals across the globe."REMAP-CAP was designed to find optimal treatments for severe pneumonia both in non-pandemic and pandemic settings. When COVID-19 began, REMAP-CAP rapidly pivoted to its pandemic mode (the REMAP-COVID substudy), as per its original intent, to incorporate additional potential treatment regimens specifically targeting COVID-19 and to expand enrollment to COVID-19 patients. This trial is a multicenter, randomized, standard of care vs. multi-active comparators platform study. The primary endpoint for the REMAP-COVID substudy is organ failure free days over a 21 day observational period. Eritoran will be evaluated in hospitalized patients in the immune modulation domain of REMAP-COVID. REMAP-CAP is led by the world's leading critical care trialists and experts in pandemic and infectious disease outbreaks, virology, immunology, emergency medicine, and Bayesian statistics. REMAP-CAP has enrolled over 1100 patients at 218 sites across North America, Europe, Australia and New Zealand. This vital research is being conducted in collaboration with Berry Consultants, leaders in statistical design for adaptive platform trials, and is being supported by governments and non-profits worldwide. Most recently, the Breast Cancer Research Foundation, committed $1M to help launch U.S. trial sites through the long-established, innovative trial infrastructure of the Translational Breast Cancer Research Consortium."The REMAP study strategy for COVID-19 provides a platform on which to build existing relevant knowledge, plus swiftly and simultaneously evaluate the safety and effectiveness of multiple investigational treatments against the virus, thus enabling us to learn as much as possible in COVID-19 clinical trials," explained Mark McClellan, M.D, PhD, Robert J. Margolis Professor of Business, Medicine, and Policy, and founding Director of the Duke-Margolis Center for Health Policy at Duke University."GCAR is honored to participate in this global effort and to serve as trial sponsor of REMAP-CAP:COVID in the U.S. alongside the University of Pittsburgh serving as the U.S. Regional Coordinating Center," shared Meredith Buxton, PhD, MPH, CEO of GCAR. "We are pleased to leverage our extensive experience in running platform trials to support this important endeavor. By working with key partners in academia, industry and philanthropy we will strive to identify improved treatment options for patients with COVID-19."To learn more about REMAP-CAP and the REMAP-COVID substudy, please visit www.remapcap.org and follow @remap_cap.

About Eisai

Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com

Contact:GCAR
Rachel Rosenstein-Sisson
rrosenstein.sisson@gcaresearch.org
+1 818-398-134

Eisai Co.,Ltd.
PR
TEL: +81(0) 3-3817-5120

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

Disparitas pemidanaan: mengapa pelaku kekerasan seksual bisa mendapat hukuman berbeda-beda untuk kasus serupa?

Ilustrasi korban kekerasan seksual.Tinnakorn jorruang/ShutterstockPraktik hukum di Indonesia masih menunjukkan adanya disparitas pemidanaan, yakni ketika ada dua orang atau lebih melakukan tindak pida...

8 aspek penting untuk memastikan keberlanjutan industri nikel dari hulu ke hilir

Isu mengenai hilirisasi nikel Indonesia tengah panas beberapa tahun ke belakang. Ambisi Presiden Joko Widodo untuk menjadikan Indonesia sentra produksi baterai kendaraan listrik (EV) dunia membuat akt...

Gangguan dismorfik tubuh: apa yang perlu kita ketahui tentang kondisi kesehatan mental ini

Selebritas Megan Fox dalam sebuah wawancara dengan Sports Illustrated mengungkapkan bahwa dia memiliki dismorfik tubuh (body dysmorphia). Fox mengatakan: “Saya tidak pernah melihat diri saya sep...



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion